*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2022 | Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression Brain, behavior, and immunity · preclinical | PMID 34343617 |
| 2021 | The time to develop treatments for diabetic neuropathy Expert opinion on investigational drugs · preclinical | PMID 33423557 |
| 2021 | Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation Cell transplantation · preclinical | PMID 34498509 |
| 2020 | Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand Transplantation · preclinical | PMID 32345869 |
| 2020 | A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema Journal of clinical medicine · preclinical | PMID 32674280 |
| 2018 | Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes Biochimica et biophysica acta. Molecular basis of disease · preclinical | PMID 29223734 |
| 2017 | Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis Scientific reports · preclinical | PMID 29026145 |
| 2017 | Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain Investigative ophthalmology & visual science · human | PMID 28475703 |
| 2016 | ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception Peptides · preclinical | PMID 26774587 |
| 2016 | A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets Transplantation · preclinical | PMID 26683514 |
| 2015 | ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes Molecular medicine (Cambridge, Mass.) · human | PMID 25387363 |
| 2014 | ARA 290 for treatment of small fiber neuropathy in sarcoidosis Expert opinion on investigational drugs · preclinical | PMID 24555851 |
ARA-290 (ARA-290 (Cibinetide; erythropoietin-derived peptide)). 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the innate-repair receptor (EPOR/CD131) for tissue-protective, anti-inflammatory effects without erythropoietic activity.
Commonly discussed uses: sarcoidosis-associated small-fibre neuropathy / neuropathic pain research (clinical trials). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the innate-repair receptor (EPOR/CD131) for tissue-protective, anti-inflammatory effects without erythropoietic activity.
Reported considerations: trials: generally well tolerated; injection-site reaction. There is both human and animal/preclinical research, though the depth and quality vary by indication. Investigational (cibinetide). Not approved. Active research interest in neuropathic pain. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low trial-defined, typical investigational (e.g. 4mg/day SC in trials), high trial-defined. Administration: subcutaneous. Half-life: ~2 minutes (short; effect outlasts exposure).
Australian status: Investigational — not approved. Investigational (cibinetide). Not approved. Active research interest in neuropathic pain. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research vials vary; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): investigational monotherapy. Stacking increases interaction/safety uncertainty.